HUP0101043A3 - Controlled release oral dosage form containing [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl]acetonitrile monohydrochlorid and process for its preparation - Google Patents
Controlled release oral dosage form containing [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl]acetonitrile monohydrochlorid and process for its preparationInfo
- Publication number
- HUP0101043A3 HUP0101043A3 HU0101043A HUP0101043A HUP0101043A3 HU P0101043 A3 HUP0101043 A3 HU P0101043A3 HU 0101043 A HU0101043 A HU 0101043A HU P0101043 A HUP0101043 A HU P0101043A HU P0101043 A3 HUP0101043 A3 HU P0101043A3
- Authority
- HU
- Hungary
- Prior art keywords
- alpha
- monohydrochlorid
- methoxyimino
- azabicyclo
- acetonitrile
- Prior art date
Links
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 title 3
- 238000013270 controlled release Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000006186 oral dosage form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Confectionery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7748098P | 1998-03-11 | 1998-03-11 | |
| US7752798P | 1998-03-11 | 1998-03-11 | |
| GBGB9805192.3A GB9805192D0 (en) | 1998-03-11 | 1998-03-11 | Composition |
| PCT/EP1999/001557 WO1999045924A1 (en) | 1998-03-11 | 1999-03-05 | Composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0101043A2 HUP0101043A2 (hu) | 2001-12-28 |
| HUP0101043A3 true HUP0101043A3 (en) | 2002-02-28 |
Family
ID=27269240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0101043A HUP0101043A3 (en) | 1998-03-11 | 1999-03-05 | Controlled release oral dosage form containing [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl]acetonitrile monohydrochlorid and process for its preparation |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6451343B1 (hu) |
| EP (1) | EP1061918A1 (hu) |
| JP (1) | JP2002506031A (hu) |
| KR (1) | KR20010034588A (hu) |
| CN (1) | CN1292696A (hu) |
| AR (1) | AR018147A1 (hu) |
| AU (1) | AU748396C (hu) |
| CA (1) | CA2323177A1 (hu) |
| CO (1) | CO5080740A1 (hu) |
| HU (1) | HUP0101043A3 (hu) |
| IL (1) | IL138192A0 (hu) |
| NO (1) | NO20004491D0 (hu) |
| NZ (1) | NZ505807A (hu) |
| PL (1) | PL342600A1 (hu) |
| TR (1) | TR200002626T2 (hu) |
| WO (1) | WO1999045924A1 (hu) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2813651B1 (fr) | 2000-09-05 | 2004-06-11 | Valeo | Appareil d'accouplement hydrocinetique, notamment pour vehicule automobile |
| BR0215262A (pt) * | 2001-12-20 | 2004-12-28 | Pharmacia Corp | Formas de dosagem com liberação sustentada de ordem zero e processo para a fabricação das mesmas |
| MY142204A (en) * | 2002-07-25 | 2010-10-29 | Pharmacia Corp | Pramipexole once-daily dosage form |
| AR040683A1 (es) * | 2002-07-25 | 2005-04-13 | Pharmacia Corp | Composicion de tabletas de liberacion sostenida que comprende un agonista de los receptores de la dopamina |
| US20050226926A1 (en) * | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
| MY136318A (en) * | 2002-07-25 | 2008-09-30 | Pharmacia Corp | Sustained-release tablet composition |
| EA200700388A1 (ru) * | 2004-08-13 | 2007-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение |
| JP4757872B2 (ja) | 2004-08-13 | 2011-08-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用 |
| WO2007090881A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Modified release formulation |
| US20090098202A1 (en) * | 2006-02-10 | 2009-04-16 | Boehringer Ingelheim International Gmbh | Extended Release Formulation |
| US20080014257A1 (en) * | 2006-07-14 | 2008-01-17 | Par Pharmaceutical, Inc. | Oral dosage forms |
| US9290759B2 (en) * | 2010-08-25 | 2016-03-22 | The Trustees Of Columbia University In The City Of New York | Optimized miRNA constructs |
| CA2992728A1 (en) | 2015-07-20 | 2017-01-26 | Acadia Pharmaceuticals Inc. | Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c |
| US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| WO2018118626A1 (en) | 2016-12-20 | 2018-06-28 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
| EP3615028A1 (en) | 2017-04-28 | 2020-03-04 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
| US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
| US11648242B2 (en) * | 2019-12-12 | 2023-05-16 | Aurobindo Pharma Ltd | Pharmaceutical composition comprising pimavanserin, process of preparation and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU207444B (en) | 1990-07-12 | 1993-04-28 | Biorex Kutato Fejlesztoe Kft | Method for producing therapeutical preparation suitable for treating alzheimer-disease |
| US5433951A (en) * | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
| GB9421472D0 (en) * | 1994-10-25 | 1994-12-07 | Smithkline Beecham Plc | Novel methods |
| AR004178A1 (es) * | 1995-07-29 | 1998-11-04 | Smithkline Beecham Plc | Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma. |
| GB9619074D0 (en) | 1996-09-12 | 1996-10-23 | Smithkline Beecham Plc | Composition |
-
1999
- 1999-03-05 CN CN998038202A patent/CN1292696A/zh active Pending
- 1999-03-05 IL IL13819299A patent/IL138192A0/xx unknown
- 1999-03-05 WO PCT/EP1999/001557 patent/WO1999045924A1/en not_active Application Discontinuation
- 1999-03-05 KR KR1020007010054A patent/KR20010034588A/ko not_active Withdrawn
- 1999-03-05 CA CA002323177A patent/CA2323177A1/en not_active Abandoned
- 1999-03-05 AU AU30332/99A patent/AU748396C/en not_active Ceased
- 1999-03-05 PL PL99342600A patent/PL342600A1/xx unknown
- 1999-03-05 JP JP2000535339A patent/JP2002506031A/ja not_active Withdrawn
- 1999-03-05 US US09/623,213 patent/US6451343B1/en not_active Expired - Fee Related
- 1999-03-05 EP EP99911765A patent/EP1061918A1/en not_active Withdrawn
- 1999-03-05 HU HU0101043A patent/HUP0101043A3/hu unknown
- 1999-03-05 TR TR2000/02626T patent/TR200002626T2/xx unknown
- 1999-03-05 NZ NZ505807A patent/NZ505807A/xx unknown
- 1999-03-09 AR ARP990100991A patent/AR018147A1/es unknown
- 1999-03-11 CO CO99015121A patent/CO5080740A1/es unknown
-
2000
- 2000-09-08 NO NO20004491A patent/NO20004491D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1061918A1 (en) | 2000-12-27 |
| PL342600A1 (en) | 2001-06-18 |
| NZ505807A (en) | 2003-01-31 |
| TR200002626T2 (tr) | 2001-03-21 |
| WO1999045924A1 (en) | 1999-09-16 |
| AU748396C (en) | 2003-01-23 |
| NO20004491L (no) | 2000-09-08 |
| AR018147A1 (es) | 2001-10-31 |
| AU3033299A (en) | 1999-09-27 |
| HUP0101043A2 (hu) | 2001-12-28 |
| AU748396B2 (en) | 2002-06-06 |
| CA2323177A1 (en) | 1999-09-16 |
| JP2002506031A (ja) | 2002-02-26 |
| KR20010034588A (ko) | 2001-04-25 |
| CN1292696A (zh) | 2001-04-25 |
| IL138192A0 (en) | 2001-11-25 |
| US6451343B1 (en) | 2002-09-17 |
| NO20004491D0 (no) | 2000-09-08 |
| CO5080740A1 (es) | 2001-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0101043A3 (en) | Controlled release oral dosage form containing [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl]acetonitrile monohydrochlorid and process for its preparation | |
| HUP0203514A3 (en) | Quinuclidine compounds and drugs containing them and process for preparation the same | |
| HUP0202100A3 (en) | Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same | |
| HUP0203542A3 (en) | 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same | |
| HUP0004024A3 (en) | Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof | |
| HUP0303398A3 (en) | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof and pharmaceutical compositions containing the same | |
| HUP0103511A3 (en) | Oxazole compounds and pharmaceutical compositions containing them and process for preparation the compounds | |
| HUP0203503A3 (en) | Pyrrolo[2,3-d]pirimidine compounds, pharmaceutical compositions containing them and their use | |
| HUP0001607A3 (en) | Thienopyrimidine derivatives, pharmaceutical compositions containing them, process for their preparation and use of the compounds | |
| HUP9800138A3 (en) | 8-substituted-1,3,8-triaza-spiro [4,5]-decan-4-on derivatives, process for producing them, pharmaceutical compositions containing the same and their use | |
| PL342345A1 (en) | Active substance suspension for oral administration | |
| HUP0201206A3 (en) | Antibacterial compounds, process for their preparation and pharmaceutical compositions containing them | |
| HUP0102215A3 (en) | Benzoylpyridazines, pharmaceutical compositions containing the same and process for their preparation | |
| IL137494A0 (en) | Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same | |
| HUP9904401A3 (en) | Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile monohydrochloride | |
| HUP0105054A3 (en) | Imidazo[4,5-c]-pyridine-4-on-derivatives, pharmaceutical compositions containing them and process for their preparation | |
| IL104706A0 (en) | 3-(1h-tetrazol-5-yl)-4h-pyrido(1,2-a)pyrimidine-4-ones and process for the preparation thereof | |
| HUP0202624A3 (en) | Pyrazolo[4,3-d]pyrimidine-derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0003577A3 (en) | Tetrahydro gamma-carbolines, process for their preparation, their use and pharmaceutical compositions containing them | |
| HUP0002650A3 (en) | 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b]-indole-1-acetamide derivatives, process for their preparation and pharmaceutical compositions containing them | |
| IL140414A0 (en) | Beta lactam compounds, processes for the preparation thereof and pharmaceutical compositions containing the same | |
| HUP0105308A3 (en) | Eletriptan hydrobromide monohydrate, process for its preparation and pharmaceutical compositions containing the same | |
| HUP9903706A3 (en) | 4,5-dihydronaphth[1,2-c]isoxazoles and derivatives thereof having cns activity, process for their preparation and pharmaceutical compositions containing the same | |
| CY2293B1 (en) | Slow-release pharmaceutical formulations containing mizolastin | |
| HUP0200376A3 (en) | Thiaoloindolinone compounds, process for their preparation and pharmaceutical composions containing them and their use |